OptiNose/OPTN

$1.69

2.42%
-
1D1W1MYTD1YMAX

About OptiNose

OptiNose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram, is a therapeutic utilizing its exhalation Delivery System (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. Its powder EDS, which is the EDS used in its ONZETRA Xsail consists of a reusable device body incorporating a flexible mouthpiece to adjust to individual anatomic variations, and a white button piercing assembly to pierce the medication capsule.

Ticker

OPTN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ramy Mahmoud

Employees

141

Headquarters

Yardley, United States

OptiNose Metrics

BasicAdvanced
$175.21M
Market cap
-
P/E ratio
-$0.39
EPS
-0.25
Beta
-
Dividend rate

What the Analysts think about OptiNose

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
77.51% upside
High $3.00
Low $3.00
$1.69
Current price
$3.00
Average price target

OptiNose Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-46.46% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$19.8M
-36.54%
Net income
$-9.2M
-43.21%
Profit margin
-46.46%
-10.52%

OptiNose Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.19%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.17
-$0.17
$0.02
-$0.08
-
Expected
-$0.17
-$0.14
-$0.11
-$0.09
-$0.09
Surprise
-2.72%
22.01%
-118.43%
-15.19%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell OptiNose stock

Buy or sell OptiNose stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing